In a groundbreaking clinical trial, every participant achieved complete remission from rectal cancer, a result previously deemed unattainable. Conducted by Memorial Sloan Kettering Cancer Center, the study involved 14 patients with mismatch repair-deficient (MMRd) rectal cancer. Over six months, they received dostarlimab, an experimental immunotherapy drug, administered every three weeks. Remarkably, all patients showed no detectable cancer through various diagnostic tests, including endoscopy, MRI, and PET scans. This outcome is unprecedented in cancer research.
05:10 AM - Feb 19, 2026
Only people mentioned by myralynnr in this post can reply
Myra Raney
@myralynnr
19 February, 05:10
In response Myra Raney to her Publication
Dostarlimab works by inhibiting the PD-1 protein on T-cells, enhancing the immune system's ability to identify and destroy cancer cells. The trial's success is attributed to the specific genetic profile of the tumors, which made them highly responsive to this treatment. None of the patients required surgery, chemotherapy, or radiation, and there were no serious side effects reported. While the results are promising, experts caution that further studies are needed to confirm the long-term efficacy and safety of dostarlimab. Nonetheless, this trial marks a significant milestone in cancer treatment, offering hope for more personalized and less invasive therapies in the future.
Notice: Undefined index: tg1tga_access in /home/admin/www/anonup.com/themes/default/apps/timeline/post.phtml on line 396
